High-risk prostate cancer: The rationale for brachytherapy

被引：0
|
作者：
Blasko, John C.
机构：
来源：
ONCOLOGY-NEW YORK | 2008年 / 22卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1016 / 1017
页数：2
相关论文
共 50 条
  • [41] Outcomes of High-Dose Rate Brachytherapy for Intermediate- to High-Risk Prostate Cancer at One Institution
    Lin, E. Y.
    Lee, A.
    Demanes, J.
    Kamrava, M.
    Venkat, P. S.
    Hagio, M. A.
    Zaide, L. B.
    Park, S. J.
    Zarate, C.
    Chang, A. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E927 - E927
  • [42] Genomics and risk stratification in high-risk prostate cancer
    Al Awamlh, Bashir Al Hussein
    Shoag, Jonathan E.
    NATURE REVIEWS UROLOGY, 2019, 16 (11) : 641 - 642
  • [43] Genomics and risk stratification in high-risk prostate cancer
    Bashir Al Hussein Al Awamlh
    Jonathan E. Shoag
    Nature Reviews Urology, 2019, 16 : 641 - 642
  • [44] Outcomes following brachytherapy boost for intermediate- and high-risk prostate cancer: A retrospective bicenter study by the SFRO brachytherapy group
    Ka, Kanta
    Schiappa, Renaud
    Terlizzi, Mario
    Mallet, Frederic
    Martin, Etienne
    Chand, Marie -Eve
    Demogeot, Nicolas
    Peiffert, Didier
    Pommier, Pascal
    Quivrin, Magali
    Kissel, Manon
    Pasquier, Corentin
    Khalifa, Jonathan
    Bossi, Alberto
    Hannoun-Levi, Jean -Michel
    Blanchard, Pierre
    RADIOTHERAPY AND ONCOLOGY, 2023, 180
  • [45] Low Dose Rate Brachytherapy Boost for High-risk Prostate Cancer: An Evidence-based Approach
    Mikropoulos, C.
    Otter, S.
    Perna, C.
    Khaksar, S.
    Franklin, A.
    Laing, R.
    Uribe, J.
    Lewis, S. U.
    Langley, S.
    CLINICAL ONCOLOGY, 2020, 32 (07) : E162 - E162
  • [46] Interstitial low dose rate brachytherapy for prostate cancer - A focus on intermediate- and high-risk disease
    Khaksar, S. J.
    Langley, S. E. M.
    Lovell, D.
    Laing, R. W.
    CLINICAL ONCOLOGY, 2006, 18 (07) : 513 - 518
  • [47] Declining brachytherapy utilization for high-risk prostate cancer-Can clinical pathways reverse the trend?
    Ling, Diane C.
    Karukonda, Pooja
    Smith, Ryan P.
    Heron, Dwight E.
    Beriwal, Sushil
    BRACHYTHERAPY, 2018, 17 (06) : 895 - 898
  • [48] Long-Term Toxicity Comparison Between Brachytherapy and Radical Prostatectomy in High-Risk Prostate Cancer
    Weller, M. A.
    Kittel, J.
    Reddy, C. A.
    Klein, E. A.
    Ulchaker, J.
    Angermeier, K.
    Campbell, S.
    Stephenson, A. J.
    Tendulkar, R. D.
    Stephans, K. L.
    Ciezki, J. P.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E237 - E238
  • [49] Enzalutamide in Men With High-Risk Biochemically Recurrent Prostate Cancer: Rationale and Treatment Considerations From EMBARK
    Shore, Neal D.
    De Giorgi, Ugo
    Freedland, Stephen J.
    JOURNAL OF UROLOGY, 2025, 213 (01): : 110 - 113
  • [50] Long-Term Outcomes of Patients With High-Risk Prostate Cancer Treated With HDR Brachytherapy Boost
    Chang, A. J.
    Roach, M.
    Gottschalk, A.
    Cunha, A. J.
    Seymour, Z. A.
    Johnson, J. A.
    Raleigh, D.
    Shinohara, K.
    Hsu, I. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S449 - S449
12345